Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Immunol Res. 2014 Nov 4;3(2):136–148. doi: 10.1158/2326-6066.CIR-14-0036

Figure 5. Tasquinimod treatment reduces the suppressive capacity of tumor-infiltrating CD11b+ cells in the CR Myc-CaP and B16-h5T4 tumor models.

Figure 5

A. CD11b+ cells were enriched from CR Myc-CaP tumors, and added at different ratios to stimulated T-cell cultures. 3[H]-thymidine was added to the cultures during the last 12 hours of 3-days culturing. B. CD11b+ cells were purified from B16-h5T4 tumors and co-cultured with purified CFSE-labeled T cells for 3 days. The frequencies of divided cells among CD4+ and CD8+ T cells were measured by FACS. C. Intracellular staining of arginase-1 and iNOS in infiltrating CD11b+ cells from CR Myc-CaP tumors. D. qRT-PCR analyses of selected genes expressed in purified CD11b+ cells from B16-h5T4 tumors. E. Intracellular staining of arginase-1 and iNOS in infiltrating CD11b+ cells isolated from B16h5T4 tumors. (*p < 0.05; **p < 0.01; ***p<0.001, t-test. Error bars indicate s.e.m.)